The FDA in early August said it would study the drugs' impact on cardiac events after two studies suggested an association with greater risk of heart attacks, heart failure and heart-related sudden death when compared to surgery.
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Monday said that following a comprehensive review, it found no evidence of a link between best-selling heartburn drugs sold by AstraZeneca Plc and heart problems.
The FDA in early August said it would study the drugs' impact on cardiac events after two studies suggested an association with greater risk of heart attacks, heart failure and heart-related sudden death when compared to surgery.
The drugs, Prilosec and Nexium, have been taken by more than 1 billion people, according to drugmaker AstraZeneca.
"Based on everything now known at the agency, the reported difference in the frequency of heart attacks and other heart-related problems seen in the earlier analyses ... does not indicate the presence of a true effect," the FDA said in a statement.
!ADVERTISEMENT!(Reporting by Kim Dixon; Editing by Maureen Bavdek)
